SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?


To: tom jones who wrote (2253)8/28/1998 2:09:00 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 4676
 
Tom,

>>I thought the committee approved Vitravene for all indications of CMV retinitis. Did something change or did I get something wrong?
Comments?<<

Committee recommended Vitravene for approval as second line drug, and rise its concern about drug efficiency (small numbers of patients in trials) as first line therapy.

Yes, I expected more from FDA approval (both indication with possibility for prophylactic usage), but was wrong.

Miljenko